Implicit to develop ex-Icos antibody for lung injury
This article was originally published in Scrip
Implicit Bioscience has acquired from Lilly a CD14-targeting antibody, which it will develop as a treatment for acute lung injury (ALI). The US major has received an undisclosed cash payment and has also taken an equity stake in the private Australian firm, which will pay royalties on future sales of the therapy.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.